Bayer in gene therapy collaboration with Mammoth Biosciences
Reuters
Published Jan 10, 2022 07:58
By Ludwig Burger and Patricia Weiss
FRANKFURT (Reuters) -Bayer on Monday struck a partnership deal with Mammoth Biosciences to develop therapeutic tools based on CRISPR/CAS9 gene editing as the German drug maker seeks to widen its cell and gene therapy development efforts.
Unlisted U.S. biotech firm Mammoth will initially receive $40 million from Bayer (DE:BAYGN) plus potential milestone payments of more than $1 billion contingent on scientific and commercial achievements.
The initial focus of the collaboration will be liver-based diseases, the companies said in a joint statement on Monday.
Mammoth, headquartered in the San Francisco Bay area, was co-founded by Nobel laureate Jennifer Doudna. She shared the 2020 Nobel Prize in Chemistry with Emmanuelle Charpentier for developing the CRISPR/CAS9 gene editing tool.
Among previous steps to build a cell and gene therapy business, Bayer acquired BlueRock Therapeutics and Asklepios Biopharmaceutical in 2019 and 2020, respectively.
In late 2020, it agreed an alliance on anti-tumour immune cell therapies with Atara Biotherapeutics.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.